Gut-Lung Microbiota in Chronic Pulmonary Diseases: Evolution, Pathogenesis, and Therapeutics

The microbiota colonized in the human body has a symbiotic relationship with human body and forms a different microecosystem, which affects human immunity, metabolism, endocrine, and other physiological processes. The imbalance of microbiota is usually linked to the aberrant immune responses and inf...

Full description

Saved in:
Bibliographic Details
Main Authors: Chang Yi Shi, Chen Huan Yu, Wen Ying Yu, Hua Zhong Ying
Format: Article
Language:English
Published: Wiley 2021-01-01
Series:Canadian Journal of Infectious Diseases and Medical Microbiology
Online Access:http://dx.doi.org/10.1155/2021/9278441
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832556356696014848
author Chang Yi Shi
Chen Huan Yu
Wen Ying Yu
Hua Zhong Ying
author_facet Chang Yi Shi
Chen Huan Yu
Wen Ying Yu
Hua Zhong Ying
author_sort Chang Yi Shi
collection DOAJ
description The microbiota colonized in the human body has a symbiotic relationship with human body and forms a different microecosystem, which affects human immunity, metabolism, endocrine, and other physiological processes. The imbalance of microbiota is usually linked to the aberrant immune responses and inflammation, which eventually promotes the occurrence and development of respiratory diseases. Patients with chronic respiratory diseases, including asthma, COPD, bronchiectasis, and idiopathic pulmonary fibrosis, often have alteration of the composition and function of intestinal and lung microbiota. Gut microbiota affects respiratory immunity and barrier function through the lung-gut microbiota, resulting in altered prognosis of chronic respiratory diseases. In turn, lung dysbiosis promotes aggravation of lung diseases and causes intestinal dysfunction through persistent activation of lymphoid cells in the body. Recent advances in next-generation sequencing technology have disclosed the pivotal roles of lung-gut microbiota in the pathogenesis of chronic respiratory diseases. This review focuses on the association between the gut-lung dysbiosis and respiratory diseases pathogenesis. In addition, potential therapeutic modalities, such as probiotics and fecal microbiota transplantation, are also evaluated for the prevention of chronic respiratory diseases.
format Article
id doaj-art-be8d9c97cbce4e2c826a50a77fe0fa1a
institution Kabale University
issn 1918-1493
language English
publishDate 2021-01-01
publisher Wiley
record_format Article
series Canadian Journal of Infectious Diseases and Medical Microbiology
spelling doaj-art-be8d9c97cbce4e2c826a50a77fe0fa1a2025-02-03T05:45:37ZengWileyCanadian Journal of Infectious Diseases and Medical Microbiology1918-14932021-01-01202110.1155/2021/9278441Gut-Lung Microbiota in Chronic Pulmonary Diseases: Evolution, Pathogenesis, and TherapeuticsChang Yi Shi0Chen Huan Yu1Wen Ying Yu2Hua Zhong Ying3Zhejiang Provincial Laboratory of Experimental Animal’s & Nonclinical Laboratory StudiesInstitute of Cancer and Basic MedicineZhejiang Provincial Laboratory of Experimental Animal’s & Nonclinical Laboratory StudiesZhejiang Provincial Laboratory of Experimental Animal’s & Nonclinical Laboratory StudiesThe microbiota colonized in the human body has a symbiotic relationship with human body and forms a different microecosystem, which affects human immunity, metabolism, endocrine, and other physiological processes. The imbalance of microbiota is usually linked to the aberrant immune responses and inflammation, which eventually promotes the occurrence and development of respiratory diseases. Patients with chronic respiratory diseases, including asthma, COPD, bronchiectasis, and idiopathic pulmonary fibrosis, often have alteration of the composition and function of intestinal and lung microbiota. Gut microbiota affects respiratory immunity and barrier function through the lung-gut microbiota, resulting in altered prognosis of chronic respiratory diseases. In turn, lung dysbiosis promotes aggravation of lung diseases and causes intestinal dysfunction through persistent activation of lymphoid cells in the body. Recent advances in next-generation sequencing technology have disclosed the pivotal roles of lung-gut microbiota in the pathogenesis of chronic respiratory diseases. This review focuses on the association between the gut-lung dysbiosis and respiratory diseases pathogenesis. In addition, potential therapeutic modalities, such as probiotics and fecal microbiota transplantation, are also evaluated for the prevention of chronic respiratory diseases.http://dx.doi.org/10.1155/2021/9278441
spellingShingle Chang Yi Shi
Chen Huan Yu
Wen Ying Yu
Hua Zhong Ying
Gut-Lung Microbiota in Chronic Pulmonary Diseases: Evolution, Pathogenesis, and Therapeutics
Canadian Journal of Infectious Diseases and Medical Microbiology
title Gut-Lung Microbiota in Chronic Pulmonary Diseases: Evolution, Pathogenesis, and Therapeutics
title_full Gut-Lung Microbiota in Chronic Pulmonary Diseases: Evolution, Pathogenesis, and Therapeutics
title_fullStr Gut-Lung Microbiota in Chronic Pulmonary Diseases: Evolution, Pathogenesis, and Therapeutics
title_full_unstemmed Gut-Lung Microbiota in Chronic Pulmonary Diseases: Evolution, Pathogenesis, and Therapeutics
title_short Gut-Lung Microbiota in Chronic Pulmonary Diseases: Evolution, Pathogenesis, and Therapeutics
title_sort gut lung microbiota in chronic pulmonary diseases evolution pathogenesis and therapeutics
url http://dx.doi.org/10.1155/2021/9278441
work_keys_str_mv AT changyishi gutlungmicrobiotainchronicpulmonarydiseasesevolutionpathogenesisandtherapeutics
AT chenhuanyu gutlungmicrobiotainchronicpulmonarydiseasesevolutionpathogenesisandtherapeutics
AT wenyingyu gutlungmicrobiotainchronicpulmonarydiseasesevolutionpathogenesisandtherapeutics
AT huazhongying gutlungmicrobiotainchronicpulmonarydiseasesevolutionpathogenesisandtherapeutics